GlassScriptPhysician profile
Jennifer I Stern
NPI 1326218157
$665.95
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $584 · 2020: $82.31.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biogen, INC. | $96.35 | 2019 | |
| Allergan, INC. | $61.64 | 2019-2020 | |
| Amgen INC. | $61.46 | 2019 | |
| Adamas Pharmaceuticals, INC. | $59.69 | 2019 | |
| Supernus Pharmaceuticals, INC. | $58.94 | 2019 | |
| Lilly USA, LLC | $50.50 | 2019 | |
| Genzyme Corporation | $47.06 | 2019 | |
| Lundbeck LLC | $33.69 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $27.82 | 2019 | |
| Alexion Pharmaceuticals, INC. | $25.56 | 2019 | |
| Emd Serono, INC. | $24.41 | 2019 | |
| Promius Pharma LLC | $20.64 | 2019 | |
| Merz North America, INC. | $19.52 | 2019 | |
| Acorda Therapeutics, INC | $19.02 | 2019 | |
| Novartis Pharmaceuticals Corporation | $18.48 | 2020 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $15.96 | 2019 | |
| W. L. Gore & Associates, INC. | $14.12 | 2019 | |
| Ucb, INC. | $11.09 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Stern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.